个性化文献订阅>期刊> Molecular Cancer Therapeutics
 

LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer

  作者 Xie, H; Valera, VA; Merino, MJ; Amato, AM; Signoretti, S; Linehan, WM; Sukhatme, VP; Seth, P  
  选自 期刊  Molecular Cancer Therapeutics;  卷期  2009年8-3;  页码  626-635  
  关联知识点  
 

[摘要]The genetic basis for the hereditary leiomyomatosis and renal cell cancer syndrome is germ-line inactivating mutation in the gene for the Krebs/tricarboxylic acid cycle enzyme, fumarate hydratase (FH), the enzyme that converts fumarate to malate. These individuals are predisposed to development of leiomyomas of the skin and uterus as well as highly aggressive kidney cancers. Inhibition of FH should result in significant decrease in oxidative phosphorylation necessitating that glycolysis followed by fermentation of pyruvate to lactate will be required to provide adequate ATP as well as to regenerate NAD(+). Moreover, FH deficiency is known to up-regulate expression of hypoxia-inducible factor (HIF)-1 alpha by enhancing the stability of HIF transcript. This leads to activation of various HIF-regulated genes including vascular endothelial growth factor and glucose transporter GLUT1 and increased expression of several glycolytic enzymes. Because lactate dehydrogenase-A (LDH-A), also a HIF-1 alpha target, promotes fermentative glycolysis (conversion of pyruvate to lactate), a step essential for regenerating NAD(+), we asked whether FH-deficient cells would be exquisitely sensitive to LDH-A blockade. Here, we report that hereditary leiomyomatosis and renal cell cancer tumors indeed overexpress LDH-A, that LDH-A inhibition results in increased apoptosis in a cell with FH deficiency and that this effect is reactive oxygen species mediated, and that LDH-A knockdown in the background of FH knockdown results in significant reduction in tumor growth in a xenograft mouse model. [Mol Cancer Ther 2009;8(3):626 - 35]

 
      被申请数(0)  
 

[全文传递流程]

一般上传文献全文的时限在1个工作日内